To examine the effectiveness of hyperthermia combined with PD-1 inhibitors and chemotherapy in patients specifically diagnosed with PD-L1 CPS-negative advanced gastric carcinoma.
Key Findings:
The CIH cohort showed significantly longer PFS compared to the CI group (P = 0.00037 and P = 0.0011).
The CIH group experienced lower rates of fatigue and anorexia (P<0.05).
Circulating tumor cell counts increased in both groups post-treatment, but the CIH cohort had higher post-treatment counts (P<0.001), indicating a potential link to enhanced immune activation.
Interpretation:
Hyperthermia combined with PD-1 blockade and chemotherapy significantly improves PFS and reduces certain adverse effects in PD-L1 CPS-negative advanced gastric cancer patients, suggesting enhanced immune activation through potential mechanisms such as increased antigen presentation and immune cell infiltration.
Limitations:
Retrospective design limits causal inference.
Small sample size may affect generalizability and the robustness of the findings.
Further validation of CTC dynamics is needed.
Conclusion:
Incorporating hyperthermia with PD-1 inhibitors and chemotherapy may enhance treatment outcomes for patients with PD-L1 CPS-negative advanced gastric cancer, warranting further investigation.
